Bavarian Nordic Announces Interim Results for the First Three Months of 2019

NEXT STORY
Centauri’s AlphamerTM Platform highlighted at 4th Annual Advances in Immuno-Oncology Congress
PREV STORY
Novartis phase II data for new inhaled combination treatment (QVM149) demonstrates significant improvements over current standard-of-care inhaled treatment
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Carrick Therapeutics Presents Encouraging Clinical Data for Samuraciclib (CT7001) at the 2021 San Antonio Breast Cancer Symposium

author_avatar
NASDAQ Market News

Aptose Reports Results for the First Quarter 2021

author_avatar
NASDAQ Market News

Menarini Group and Radius Health Announce Positive Phase 3 Topline Results from the EMERALD Trial Evaluating Elacestrant in Breast Cancer

author_avatar
NASDAQ Market News